论文部分内容阅读
目的探讨瑞格列奈联合二甲双胍对中青年2型糖尿病的治疗效果。方法选择我院确诊2型糖尿病的中青年患者32例,年龄30~50岁,入院后在对患者进行糖尿病健康教育,控制饮食,配合运动,心理疏导等基础上,给予患者二甲双胍0.25~0.5mg,3次/d餐中或餐后口服,瑞格列奈起始剂量为0.5mg,3次/d餐前口服,依据血糖水平调整用量。所有患者均于治疗前、治疗后12周内监测空腹血糖(FBG)、餐后2h血糖(2hBG)、糖化血红蛋白(HbAlc)的变化。结果所有病例经过治疗后血糖平稳下降,治疗1个月后患者空腹血糖5.3~8.0 mmol/L,3个月后空腹血糖5.1~6.8 mmol/L,糖化血红蛋白6.0%~7.4%。治疗12周后,FBG、2hBG、HbAlc均较治疗前明显降低,尤其HbAlc达标率明显提高。血糖的控制和糖化血红蛋白与治疗前比明显好转,无一例低血糖发生,也无明显其他不良反应。结论瑞格列奈联合二甲双胍治疗中青年2型糖尿病能够良好地控制高血糖,且低血糖发生率低,无明显不良反应,有效、方便、依从性高,是中青年2型糖尿病人的理想治疗手段。
Objective To investigate the effect of repaglinide combined with metformin on type 2 diabetes mellitus in middle-aged and young patients. Methods Thirty-two middle-aged and young patients with type 2 diabetes diagnosed in our hospital were selected. Their ages ranged from 30 to 50 years old. After admission, patients were given diabetes mellitus education, diet control, coordination exercise and psychological counseling. Patients were given metformin 0.25-0.5 mg , 3 times / d meal or postprandial oral, repaglinide initial dose of 0.5mg, 3 times / d before meals orally, adjust the dosage based on blood glucose levels. All patients were monitored for fasting blood glucose (FBG), 2h postprandial glucose (2hBG), and HbAlc changes within 12 weeks after treatment. Results After treatment, the blood glucose level decreased steadily in all cases. The fasting blood glucose was 5.3-8.0 mmol / L after 1 month of treatment. The fasting blood glucose level was 5.1-6.8 mmol / L after 3 months and 6.0-7.4% of HbA1c levels. After 12 weeks of treatment, FBG, 2hBG, HbAlc were significantly lower than before treatment, especially the HbAlc compliance rate was significantly improved. Blood sugar control and glycosylated hemoglobin and treatment significantly improved, no case of hypoglycemia, no obvious other adverse reactions. Conclusion The combination of repaglinide with metformin in middle-aged and young patients with type 2 diabetes can control hyperglycemia well with low incidence of hypoglycemia and no obvious adverse reactions, which is effective, convenient and high compliance and is ideal for middle-aged and young patients with type 2 diabetes means.